$5.85 Billion in Sales Expected for Gilead Sciences, Inc. (NASDAQ:GILD) This Quarter

Equities analysts expect Gilead Sciences, Inc. (NASDAQ:GILDGet Rating) to post sales of $5.85 billion for the current fiscal quarter, Zacks Investment Research reports. Eight analysts have made estimates for Gilead Sciences’ earnings. The lowest sales estimate is $5.50 billion and the highest is $6.42 billion. Gilead Sciences posted sales of $6.22 billion during the same quarter last year, which would indicate a negative year over year growth rate of 5.9%. The business is scheduled to announce its next earnings results on Monday, January 1st.

On average, analysts expect that Gilead Sciences will report full year sales of $24.64 billion for the current financial year, with estimates ranging from $24.16 billion to $25.77 billion. For the next fiscal year, analysts forecast that the business will report sales of $23.95 billion, with estimates ranging from $23.20 billion to $24.82 billion. Zacks’ sales calculations are an average based on a survey of analysts that that provide coverage for Gilead Sciences.

Gilead Sciences (NASDAQ:GILDGet Rating) last announced its quarterly earnings results on Thursday, April 28th. The biopharmaceutical company reported $2.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.35. Gilead Sciences had a return on equity of 44.98% and a net margin of 16.43%. The company had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.28 billion. During the same period in the prior year, the company earned $2.08 earnings per share. The company’s revenue for the quarter was up 2.6% compared to the same quarter last year.

GILD has been the subject of several recent research reports. Wells Fargo & Company reduced their price target on Gilead Sciences from $70.00 to $63.00 and set an “equal weight” rating for the company in a research report on Tuesday, March 22nd. Maxim Group reduced their price target on Gilead Sciences from $88.00 to $84.00 in a research report on Thursday, February 3rd. Barclays reduced their price target on Gilead Sciences from $63.00 to $56.00 and set an “underweight” rating for the company in a research report on Thursday, March 10th. Mizuho reduced their price target on Gilead Sciences from $81.00 to $75.00 and set a “buy” rating for the company in a research report on Tuesday, February 8th. Finally, Truist Financial reduced their price target on Gilead Sciences from $77.00 to $75.00 and set a “hold” rating for the company in a research report on Wednesday, February 2nd. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $72.20.

GILD stock opened at $65.01 on Thursday. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.48 and a quick ratio of 1.30. The stock has a market capitalization of $81.54 billion, a P/E ratio of 18.16, a P/E/G ratio of 0.45 and a beta of 0.38. The business has a 50-day moving average of $61.43 and a 200-day moving average of $65.12. Gilead Sciences has a fifty-two week low of $57.19 and a fifty-two week high of $74.12.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, June 29th. Stockholders of record on Wednesday, June 15th will be paid a dividend of $0.73 per share. The ex-dividend date is Tuesday, June 14th. This represents a $2.92 dividend on an annualized basis and a dividend yield of 4.49%. Gilead Sciences’s dividend payout ratio (DPR) is currently 81.56%.

In other news, EVP Brett A. Pletcher sold 3,634 shares of the stock in a transaction that occurred on Friday, March 11th. The stock was sold at an average price of $58.24, for a total transaction of $211,644.16. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 0.16% of the stock is currently owned by company insiders.

A number of institutional investors have recently bought and sold shares of GILD. OLD Second National Bank of Aurora boosted its stake in shares of Gilead Sciences by 46.3% during the 3rd quarter. OLD Second National Bank of Aurora now owns 439 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 139 shares during the last quarter. Key Financial Inc lifted its stake in shares of Gilead Sciences by 3.7% during the 4th quarter. Key Financial Inc now owns 4,228 shares of the biopharmaceutical company’s stock valued at $307,000 after buying an additional 151 shares in the last quarter. Trust Investment Advisors lifted its stake in shares of Gilead Sciences by 1.3% during the 4th quarter. Trust Investment Advisors now owns 12,243 shares of the biopharmaceutical company’s stock valued at $889,000 after buying an additional 153 shares in the last quarter. Equitable Holdings Inc. lifted its stake in shares of Gilead Sciences by 0.4% during the 3rd quarter. Equitable Holdings Inc. now owns 41,253 shares of the biopharmaceutical company’s stock valued at $2,882,000 after buying an additional 156 shares in the last quarter. Finally, Certified Advisory Corp increased its holdings in Gilead Sciences by 1.1% in the 3rd quarter. Certified Advisory Corp now owns 14,297 shares of the biopharmaceutical company’s stock valued at $999,000 after acquiring an additional 161 shares during the last quarter. Hedge funds and other institutional investors own 80.16% of the company’s stock.

About Gilead Sciences (Get Rating)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.

Read More

Get a free copy of the Zacks research report on Gilead Sciences (GILD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.